ViroGates announces that it has completed the development and regulatory approval (CE-IVD) of its suPARnostic® TurbiLatex product for the ADVIA® Chemistry XPT System from Siemens Healthineers.

suPARnostic® will now be available for clinical decision making at Sygehus Lillebaelts two hospitals in Kolding and Vejle, Denmark. Both hospitals use the cobas system from Roche Diagnostics, an instrument line that was validated by ViroGates for use of the suPARnostic® TurbiLatex test earlier this year.

Read the Journal "suPAR News" No. 2, 2019 - with lots of interesting articles and interviews from around Europe!

suPARnostic® will now be available for clinical decision making in the University Hospital of Montpellier, France.
It will be the first hospital in the world to run suPARnostic® TurbiLatex at the Roche cobas 8000 system.

ViroGates and QIAGEN announces a partnership to launch suPARnostic® Quick Triage on QIAGEN’s automated Lateral Flow (aLF) platform.

ViroGates is expanding and has employed yet another two employees; new Global Partner Director and new CFO.